FIC20230026I1 - Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon) - Google Patents

Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon)

Info

Publication number
FIC20230026I1
FIC20230026I1 FIC20230026C FIC20230026C FIC20230026I1 FI C20230026 I1 FIC20230026 I1 FI C20230026I1 FI C20230026 C FIC20230026 C FI C20230026C FI C20230026 C FIC20230026 C FI C20230026C FI C20230026 I1 FIC20230026 I1 FI C20230026I1
Authority
FI
Finland
Prior art keywords
etranacogen
dezaparvovec
padua
hemophilia
adeno
Prior art date
Application number
FIC20230026C
Other languages
English (en)
Original Assignee
Uniqure Biopharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FIC20230026(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B V filed Critical Uniqure Biopharma B V
Publication of FIC20230026I1 publication Critical patent/FIC20230026I1/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FIC20230026C 2008-09-15 2023-07-25 Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon) FIC20230026I1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione

Publications (1)

Publication Number Publication Date
FIC20230026I1 true FIC20230026I1 (fi) 2023-07-25

Family

ID=41397565

Family Applications (4)

Application Number Title Priority Date Filing Date
FIEP19174517.3T FI3581650T3 (fi) 2008-09-15 2009-09-15 IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
FIC20230026C FIC20230026I1 (fi) 2008-09-15 2023-07-25 Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon)
FIC20240037C FIC20240037I1 (fi) 2008-09-15 2024-10-29 Fidanakogeenielaparvoveekki
FIC20240036C FIC20240036I1 (fi) 2008-09-15 2024-10-29 Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FIEP19174517.3T FI3581650T3 (fi) 2008-09-15 2009-09-15 IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi

Family Applications After (2)

Application Number Title Priority Date Filing Date
FIC20240037C FIC20240037I1 (fi) 2008-09-15 2024-10-29 Fidanakogeenielaparvoveekki
FIC20240036C FIC20240036I1 (fi) 2008-09-15 2024-10-29 Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L

Country Status (18)

Country Link
US (11) US9249405B2 (fi)
EP (5) EP3252157A1 (fi)
CA (1) CA2737094C (fi)
CY (2) CY1125885T1 (fi)
DK (2) DK3581650T3 (fi)
ES (3) ES2940323T3 (fi)
FI (4) FI3581650T3 (fi)
FR (1) FR23C1028I1 (fi)
HK (1) HK1244507A1 (fi)
HR (2) HRP20230259T1 (fi)
HU (3) HUE067487T2 (fi)
LT (2) LT3581650T (fi)
NO (1) NO2023029I1 (fi)
PL (3) PL2337849T3 (fi)
PT (1) PT3581650T (fi)
SI (1) SI3581650T1 (fi)
TR (1) TR201813067T4 (fi)
WO (1) WO2010029178A1 (fi)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252157A1 (en) 2008-09-15 2017-12-06 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
WO2014018120A1 (en) 2012-07-25 2014-01-30 Catalyst Biosciences, Inc. Modified factor x polypeptides and uses thereof
PL3889173T3 (pl) 2013-02-15 2023-12-11 Bioverativ Therapeutics Inc. Zoptymalizowany gen czynnika viii
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
KR102415896B1 (ko) 2015-06-23 2022-06-30 더 칠드런스 호스피탈 오브 필라델피아 변형된 인자 ix, 및 세포, 기관 및 조직으로 유전자를 전달하기 위한 조성물, 방법 및 용도
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
IL263801B2 (en) 2016-07-26 2024-01-01 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
CN116732066A (zh) * 2016-10-14 2023-09-12 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
CN118581121A (zh) 2017-05-22 2024-09-03 武田药品工业株式会社 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
EA202090260A1 (ru) 2017-07-10 2020-05-08 ЮНИКЬЮРЕ АйПи Б.В. Средства и способы для генотерапии aav у человека
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
SG11202010830WA (en) 2018-05-09 2020-11-27 Biomarin Pharm Inc Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
AU2019270972A1 (en) 2018-05-14 2020-12-03 Biomarin Pharmaceutical Inc. Stable expression of AAV vectors in juvenile subjects
AU2019323747A1 (en) * 2018-08-20 2021-03-04 Ucl Business Ltd Factor ix encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
UY38389A (es) * 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
WO2023275024A1 (en) * 2021-07-01 2023-01-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
AU710069B2 (en) 1996-06-11 1999-09-16 Roche Diagnostics Gmbh Recombinant blood-coagulation proteases
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
EP0971724B1 (en) 1997-02-14 2010-01-20 American Red Cross Expression of active human factor ix in mammary tissue of transgenic animals
WO1999003496A1 (en) * 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
EP1427820A2 (en) 2001-09-04 2004-06-16 MERCK PATENT GmbH Modified factor ix
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US20060292117A1 (en) * 2002-04-17 2006-12-28 Loiler Scott A Improved rAAv vectors
SG188669A1 (en) 2002-10-02 2013-04-30 Catalyst Biosciences Inc Method of generating and screening for proteases with altered specificity
JP4559429B2 (ja) * 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP1781782B1 (en) 2004-08-17 2010-05-26 CSL Behring GmbH Modified vitamin k dependent polypeptides
EP1627771B1 (de) 2004-08-19 2008-10-15 Gerd Bär Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
ES2436741T3 (es) * 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7892809B2 (en) 2004-12-15 2011-02-22 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2428218A1 (en) 2005-10-21 2012-03-14 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
SI1969127T2 (sl) 2005-12-21 2017-10-30 Cnj Holdings, Inc Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami
WO2007089632A2 (en) 2006-01-27 2007-08-09 The University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
US7375084B2 (en) * 2006-03-07 2008-05-20 Baxter International Inc. Highly phosphorylated and sulfated recombinant factor IX
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
EP2007795B1 (en) * 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
JP5479087B2 (ja) * 2006-04-07 2014-04-23 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム アデノ随伴ウイルスファージ粒子に関する方法および組成物
MX2008014685A (es) 2006-05-24 2008-11-27 Novo Nordisk Healthcare Ag Analogos de factor ix con semivida prolongada in vivo.
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US8198421B2 (en) 2006-06-19 2012-06-12 Asklepios Biopharmaceutical, Inc. Modified factor VIII and factor IX genes and vectors for gene therapy
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP2108045B1 (en) * 2007-02-01 2013-12-11 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
WO2008127654A2 (en) 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
AU2008311973B2 (en) 2007-10-15 2013-10-03 Cangene Corporation Human Factor IX variants with an extended half life
AU2009244633A1 (en) * 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified Factor IX polypeptides and uses thereof
WO2009140015A2 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP3252157A1 (en) 2008-09-15 2017-12-06 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
JP5909180B2 (ja) 2009-06-25 2016-04-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル キメラ第ｖｉｉ因子分子
BR112012002072A2 (pt) 2009-07-31 2016-11-08 Bayer Healthcare Llc polipeptídeos de fator ix modificados e usos dos mesmos
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
KR102415896B1 (ko) 2015-06-23 2022-06-30 더 칠드런스 호스피탈 오브 필라델피아 변형된 인자 ix, 및 세포, 기관 및 조직으로 유전자를 전달하기 위한 조성물, 방법 및 용도
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения

Also Published As

Publication number Publication date
HRP20181442T1 (hr) 2018-12-14
US20220090042A1 (en) 2022-03-24
PL2337849T3 (pl) 2018-11-30
US20170355973A1 (en) 2017-12-14
EP3581650A2 (en) 2019-12-18
WO2010029178A1 (en) 2010-03-18
US20160122740A1 (en) 2016-05-05
EP3252157A1 (en) 2017-12-06
US20200199564A1 (en) 2020-06-25
FIC20240037I1 (fi) 2024-10-30
SI3581650T1 (sl) 2023-06-30
EP2337849A1 (en) 2011-06-29
US20220002702A1 (en) 2022-01-06
US20200190498A1 (en) 2020-06-18
CA2737094C (en) 2018-02-20
EP4032979B1 (en) 2024-05-01
HUE061345T2 (hu) 2023-06-28
DK3581650T3 (da) 2023-03-13
PT3581650T (pt) 2023-03-08
FI3581650T3 (fi) 2023-03-23
CA2737094F (en) 2010-03-18
CA2737094A1 (en) 2010-03-18
US10465180B2 (en) 2019-11-05
US9982248B2 (en) 2018-05-29
ES2985035T3 (es) 2024-11-04
ES2687038T3 (es) 2018-10-23
EP4219547A3 (en) 2023-10-18
HUS2300024I1 (hu) 2023-08-28
PL4032979T3 (pl) 2024-09-30
US20210214704A1 (en) 2021-07-15
CY1125885T1 (el) 2024-02-16
HK1244507A1 (zh) 2018-08-10
ES2940323T3 (es) 2023-05-05
US9249405B2 (en) 2016-02-02
HUE067487T2 (hu) 2024-10-28
CY2023016I1 (el) 2024-02-16
EP3581650A3 (en) 2020-03-25
US20180258413A1 (en) 2018-09-13
US20200231958A1 (en) 2020-07-23
TR201813067T4 (tr) 2018-09-21
HRP20230259T1 (hr) 2023-04-28
EP3581650B1 (en) 2022-12-28
EP4032979A1 (en) 2022-07-27
FR23C1028I1 (fr) 2023-10-06
CY2023016I2 (el) 2024-02-16
US20210238573A1 (en) 2021-08-05
EP2337849B1 (en) 2018-06-13
EP4032979C0 (en) 2024-05-01
NO2023029I1 (no) 2023-07-31
LTPA2023521I1 (fi) 2023-08-25
LT3581650T (lt) 2023-05-10
DK2337849T3 (en) 2018-10-01
EP4219547A2 (en) 2023-08-02
FIC20240036I1 (fi) 2024-10-29
PL3581650T3 (pl) 2023-05-22
US20110244550A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
FIC20230026I1 (fi) Etranakogeenidetsaparvoveekki (adenoassosioitu virusvektori, joka sisältää ihmisen hyytymistekijä IX:n geenin koodonioptimoitua Padua-johdannaista B-hemofilian hoitoon)
BR112012004546A2 (pt) "terapêutica por proteínas ligantes dll4-ligantes"
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2488242T3 (da) Medicinsk indåndingsmaske
FR2958549B1 (fr) Appareil d'assistance respiratoire.
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
ITMI20111404A1 (it) Supporto per articolazioni umane.
EP2598149A4 (en) SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
BR112012004377A2 (pt) terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
BRPI0917567A2 (pt) tratamento de doença respiratória
DK2236149T3 (da) Medicinsk sammensætning til behandling af respiratoriske infektions-sygdomme
SMT201600189B (it) Soluzione acquosa comprendente 3-chinuclidinoni per il trattamento di malattie iperproliferative, autoimmuni e cardiache
ZA201403549B (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
IL207595A0 (en) Cardioplegia solution for cardiac surgery
IT1402018B1 (it) Formulazioni per il trattamento delle affezioni delle prime vie respiratorie.
ZA201004888B (en) Use of an acetylsalicyclic acid salt for the treatment of viral infections
WO2011163566A3 (en) Methods of treating patients with immune-related diseases
BRPI0921947A2 (pt) formulações de proteína terapêutica
BRPI1013799A2 (pt) eletrodos de desfibrilação.
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
BRPI1014904A2 (pt) derivados de quinazolinadiona, preparação dos mesmos e vários usos terapêuticos dos mesmos.
DK2200585T3 (da) Anvendelse af deuteriumoxid til behandling af virusbaserede hudsygdomme
IT1400666B1 (it) Procedimento per la sintesi di 5-amino, 1-fenil, 3-ciano, 4-trifluorometil sulfinil pirazoli.
FI20080262A (fi) Sykeharvesteri tai prosessori